The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancerThomas G. Hopkins, Sarah P. Blagden, Manuela Mura et al.|Nucleic Acids Research|2015Cited by 164
The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinomaEuan A. Stronach, Mona El‐Bahrawy|Oncotarget|2015Cited by 48
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studySarah P. Blagden, Essam Ghazaly, Puvan Suppiah et al.|British Journal of Cancer|2018Cited by 43
Dose-Finding Quantitative <sup>18</sup>F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic MalignanciesHatice Güngör, Hani Gabra, Azeem Saleem et al.|Journal of Nuclear Medicine|2015Cited by 27
Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.Hatice Güngör, Hani Gabra, Azeem Saleem et al.|Journal of Clinical Oncology|2011Cited by 14